Sanofi S.A.

… Novo's Victoza. Novo investors are also worried about Sanofi 's ( SNY +2.4% ) Lantus and a combination of the product with another drug called Lyxumia. Sanofi is scheduled to present at the conference as well but …

June 10 (Reuters) - French drugmaker Sanofi SA said the U.S. Food and Drug Administration had approved its four-strain influenza vaccine, which is meant to provide better protection from infection than traditional three-strain flu vaccines.

Sanofi ( SNY +0.1% ) hopes the European Medicines Agency will give the green light ..... but its patents are due to run out over the next few years. However, if Sanofi can get the IP protection extended and overcome safety concerns, it could …

PARIS, June 10 (Reuters) - Sanofi SA said on Monday that its Sanofi Pasteur vaccines division has won clearance from the U.S. Food and Drug Administration to market its four-strain influenza vaccine, Fluzone Quadrivalent.

… has "positive growth inflection potential" in FY14; AbbVie ( ABBV +0.6% ), Roche ( RHHBY.OB +2.5% ), and Sanofi ( SNY +0.5% ) offer "attractive entry points" but ABBV's PT is lowered to $51 from $54; Johnson & Johnson's …

… for this form of skin cancer. In another trial, 68.9% of melanoma patients who took BMY's Yervoy together with Sanofi 's ( SNY ) Leukine were alive a year later vs 52.9% of those who received just Yervoy. The findings were presented at the …

… Companies that make ARBs, which generated $7.6B in U.S. sales last year, include Novartis ( NVS ), Merck ( MRK ), Sanofi ( SNY ), Bristol-Myers Squibb ( BMY ) and AstraZeneca ( AZN ). Post your comment!